PMID 17227290
MSP, 4.3%
doi: 10.3389/fphar.2024.1345522 Received 28 November 2023 Accepted 23 February 2024 Published 06 March 2024 Volume 15 - 2024 Edited by Shuangiqan Yan, Fujian Normal University, China Reviewed by Linchong Sun, Guangdong Academy of Medical Sciences, China Yufeng Xiao, University of Florida, United States Updates Copyright 2024 Fan, Xue, Li, Huo, Gao and Guan
This product is contraindicated in individuals with a known hypersensitivity to phospholipids, or any of the listed ingredients
DeNicola GM, Karreth FA, Humpton TJ, Gopinathan A, Wei C, Frese K, Mangal D, Yu KH, Yeo CJ, Calhoun ES, Scrimieri F, Winter JM, Hruban RH, Iacobuzio-Donahue C, Kern SE, Blair IA, Tuveson DA